Rep. David Taylor Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 11/3/2026.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $16.77 on Friday, reaching $1,444.05. The stock had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The stock has a market cap of $1.36 trillion, a P/E ratio of 46.87, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The business’s 50-day moving average price is $1,242.25 and its two-hundred day moving average price is $1,110.30. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $7.02 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp increased its holdings in Eli Lilly and Company by 1.7% in the third quarter. State Street Corp now owns 36,848,565 shares of the company’s stock valued at $42,636,738,000 after purchasing an additional 632,811 shares during the last quarter. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the second quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after buying an additional 137,364 shares during the period. Finally, Jennison Associates LLC lifted its stake in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here’s some of the latest news about LLY:

• Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
• Neutral Sentiment: Lilly is advancing an early-stage ALS drug study, but investors are still waiting for clinical data, so the update does not yet establish whether the treatment will succeed. Eli Lilly advances early ALS drug study

Wall Street Analyst Weigh In

A number of analysts recently weighed in on LLY shares. The Goldman Sachs Group reissued a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. TD Cowen restated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. HSBC lifted their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research note on Tuesday, September 15th. Finally, Weiss Ratings cut Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.